GNI Group (TYO:2160) said its core subsidiary, Gyre Therapeutics, completed a public offering of common stock, raising about $23 million in gross proceeds, according to a Monday filing on the Tokyo Stock Exchange.
The offering closed on May 29, with Gyre issuing 2,555,555 shares at $9 apiece, including 333,333 shares from the underwriters' overallotment option, the filing said.
GNI said its ownership in Gyre has decreased to 80.69% from 83.03%, though the unit remains a consolidated subsidiary of the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。